- Home
- REPX vs CERT Comparison
REPX vs CERT Comparison
Compare REPX & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REPX | CERT |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 776.6M | 860.9M |
| IPO Year | 2003 | 2020 |
Fundamental Metrics
Financial Performance| Metric | REPX | CERT |
|---|---|---|
| Price | $36.25 | $4.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $45.00 | $11.67 |
| AVG Volume (30 Days) | 419.4K | ★ 2.7M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | 78.17 | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | $3,038,000.00 | ★ $418,838,000.00 |
| Revenue This Year | $33.41 | $4.18 |
| Revenue Next Year | $13.46 | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $24.08 | $4.97 |
| 52 Week High | $41.26 | $13.88 |
Technical Indicators
Market Signals| Indicator | REPX | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 26.57 |
| Support Level | $33.49 | N/A |
| Resistance Level | $37.08 | $6.48 |
| Average True Range (ATR) | 1.50 | 0.33 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 83.06 | 0.30 |
Price Performance
Historical ComparisonAbout REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations include: The Permian Basin is an oil and natural gas producing area located in West Texas.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.